Pharmacologic Interventions in Nuclear Radiology: Indications, Imaging Protocols, and Clinical Results
Abstract
Nuclear radiology is valuable in assessing pathophysiology of a variety of organ systems. Pharmacologic interventions are often employed in radionuclide imaging to monitor the physiologic changes, which in turn facilitate the diagnosis. Metoclopramide, erythromycin, and cisapride have been used for gastric emptying studies. To overcome false-negative results, cimetidine, pentagastrin, and glucagon have been used in imaging of Meckel diverticula. Pharmacologic intervention with either cholecystokinin-8 or morphine is used primarily for the assessment of diseases of the gallbladder, common bile duct, and sphincter of Oddi. Pharmacologic interventions performed during renography include diuretic administration, angiotensin-converting enzyme inhibition, and aspirin renography. Recombinant thyrotropin can be used in patients with previously treated thyroid carcinoma who require lifelong follow-up for recurrent disease. Cardiac pharmacologic stress agents fall into two categories: coronary vasodilating agents, such as dipyridamole and adenosine, and cardiac positive inotropic agents, such as dobutamine and arbutamine. Measurement of hemodynamic responses to pharmacologic flow augmentation with carbon dioxide or acetazolamide is valuable in cerebrovascular perfusion studies.
© RSNA, 2002
References
- 1 Fine EJ. Interventions in renal scintirenography. Semin Nucl Med 1999; 2:128-145.
- 2 Datz FL, Christian PE, Hutson WR, et al. Physiological and pharmacological interventions in radionuclide imaging of the tubular gastrointestinal tract. Semin Nucl Med 1991; 21:140-152.
- 3 Urbain JL, Vekemans MC, Parkman H, et al. Dynamic antral scintigraphy to characterize gastric antral motility in functional dyspepsia. J Nucl Med 1995; 36:1579-1586.
- 4 Watkins PJ. Diabetic autonomic neuropathy. N Engl J Med 1990; 322:1078-1079.
- 5 Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin: preliminary studies. N Engl J Med 1990; 322:1028-1031.
- 6 Urbain JL, Vantrappen G, Janssens J, et al. Intravenous erythromycin dramatically accelerates gas-tric emptying in diabeticorum and normals and abolishes the emptying discrimination between solids and liquids. J Nucl Med 1990; 31:1490-1493.
- 7 Delatour F, Le Guludec D, Caron F, et al. Effect of a single oral dose of two erythromycin ethylsuccinate formulations on gastric emptying in healthy volunteers: a scintigraphic study. Fundam Clin Pharmacol 1998; 12:292-297.
- 8 Urbain JL, Siegel JA, Debie NC, et al. Effect of cisapride on gastric emptying in dyspeptic patients. Dig Dis Sci 1988; 33:779-783.
- 9 Richards RD, Valenzuela GA, Davenport KG, et al. Objective and subjective results of a randomized, double-blind, placebo-controlled trial using cisapride to treat gastroparesis. Dig Dis Sci 1993; 38:811-816.
- 10 Connolly LP, Treves ST, Bozorgi F, O’Conner SC. Meckel’s diverticulum: demonstration of heterotopic gastric mucosa with technetium-99m-pertechnetate SPECT. J Nucl Med 1998; 39:1458-1460.
- 11 St-Vil D, Brandt ML, Panic S, Bensoussan AL, Blanchard H. Meckel’s diverticulum in children: a 20-year review. J Pediatr Surg 1991; 26:1289-1292.
- 12 Sfakianakis GN, Anderson GF, King DR, Boles ET, Jr. The effect of gastrointestinal hormones on the pertechnetate imaging of ectopic gastric mucosa in experimental Meckel’s diverticulum. J Nucl Med 1981; 22:678-683.
- 13 Yeker D, Buyukunal C, Benli M, Buyukunal E, Urgancioglu I. Radionuclide imaging of Meckel’s diverticulum: cimetidine versus pentagastrin plus glucagon. Eur J Nucl Med 1984; 9:316-319.
- 14 Diamond RH, Rothstein RD, Alavi A. The role of cimetidine-enhanced technetium-99m-pertechnetate imaging for visualizing Meckel’s diverticulum. J Nucl Med 1991; 32:1422-1424.
- 15 Heyman S. Meckel’s diverticulum: possible detection by combining pentagastrin with histamine H2 receptor blocker. J Nucl Med 1994; 35:1656- 1658.
- 16 Treves S, Grand RJ, Eraklis AJ. Pentagastrin stimulation of technetium-99m uptake by ectopic gastric mucosa in a Meckel’s diverticulum. Radiology 1978; 128:711-712.
- 17 Krishnamurthy S, Krishnamurthy GT. Cholecystokinin and morphine pharmacological intervention during 99mTc-HIDA cholescintigraphy: a rational approach. Semin Nucl Med 1996; 26:16-24.
- 18 Fink-Bennett D, Balon H, Robbins T, Tsai D. Morphine-augmented cholescintigraphy: its efficacy in detecting acute cholecystitis. J Nucl Med 1991; 32:1231-1233.
- 19 Ziessman HA. Cholecystokinin cholescintigraphy: victim of its own success? J Nucl Med 1999; 40:2038-2042.
- 20 Chen CC, Holder LE, Maunoury C, Drachenberg CI. Morphine augmentation increases gallbladder visualization in patients pretreated with cholecystokinin. J Nucl Med 1997; 38:644-647.
- 21 Kim CK. Pharmacologic intervention for the diagnosis of acute cholecystitis: cholecystokinin pretreatment or morphine, or both? J Nucl Med 1997; 38:647-649.
- 22 Achong DM, Oates E. Normal gallbladder ejection fraction after morphine augmentation. Clin Nucl Med 1999; 24:837-841.
- 23 Nadel HR. Hepatobiliary scintigraphy in children. Semin Nucl Med 1996; 26:25-42.
- 24 Fine EJ. Interventions in renal scintigraphy. Semin Nucl Med 1999; 29:128-145.
- 25 Conway JJ, Maizels M. The “well tempered” diuretic renogram: a standard method to examine the asymptomatic neonate with hydronephrosis or hydroureteronephrosis—a report from combined meetings of The Society for Fetal Urology and members of The Pediatric Nuclear Medicine Council–The Society of Nuclear Medicine. J Nucl Med 1992; 33:2047-2051.
- 26 O’Reilly PH, Testa HJ, Lawson RS, et al. Diuresis renography in equivocal urinary tract obstruction. Br J Urol 1978; 50:76-80.
- 27 Taylor AT, Jr, Fletcher JW, Nally JV, Jr, et al. Procedure guideline for diagnosis of renovascular hypertension: Society of Nuclear Medicine. J Nucl Med 1998; 39:1297-1302.
- 28 Taylor A, Nally J, Aurell M, et al. Consensus report on ACE inhibitor renography for detecting renovascular hypertension: Radionuclides in Nephrourology Group. Consensus Group on ACEI Renography. J Nucl Med 1996; 37:1876-1882.
- 29 Nally JV, Jr, Chen C, Fine E, et al. Diagnostic criteria of renovascular hypertension with captopril renography: a consensus statement. Am J Hypertens 1991; 4:749S-752S.
- 30 Nally JV, Jr, Black HR. State-of-the-art review: captopril renography—pathophysiological considerations and clinical observations. Semin Nucl Med 1992; 22:85-97.
- 31 Imanishi M, Kawamura M, Akabane S, et al. Aspirin lowers blood pressure in patients with renovascular hypertension. Hypertension 1989; 14:461-468.
- 32 van de Ven PJ, de Klerk JM, Mertens IJ, et al. Aspirin renography and captopril renography in the diagnosis of renal artery stenosis. J Nucl Med 2000; 41:1337-1342.
- 33 Ladenson PW. Recombinant thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma. Semin Nucl Med 2000; 30:98-106.
- 34 Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997; 337:888-896.
- 35 Weintraub BD, Szkudlinski MW. Development and in vitro characterization of human recombinant thyrotropin. Thyroid 1999; 9:447-450.
- 36 Meier CA, Braverman LE, Ebner SA, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994; 78:188-196.
- 37 Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84:3877-3885.
- 38 Travin MI, Wexler JP. Pharmacological stress testing. Semin Nucl Med 1999; 29:298-318.
- 39 Cohen MC. A snapshot of nuclear cardiology in the United States. Am Soc Nucl Cardiol Newsletter 1998; 5:13.
- 40 Santos-Ocampo CD, Herman SD, Travin MI, et al. Comparison of exercise, dipyridamole, and adenosine by use of technetium-99m sestamibi tomographic imaging. J Nucl Cardiol 1994; 1:57-64.
- 41 Miller DD, Younis LT, Chaitman BR, et al. Diagnostic accuracy of dipyridamole technetium 99m-labeled sestamibi myocardial tomography for detection of coronary artery disease. J Nucl Cardiol 1997; 4:18-24.
- 42 Lette J, Tatum JL, Fraser S, et al. Safety of dipyridamole testing in 73,806 patients: the Multicenter Dipyridamole Safety. J Nucl Cardiol 1995; 2:3-17.
- 43 Taillefer R, Amyot R, Turpin S, et al. Comparison between dipyridamole and adenosine as pharmacologic coronary vasodilators in detection of coronary artery disease with thallium 201 imaging. J Nucl Cardiol 1996; 3:204-211.
- 44 Pearlman JD, Boucher CA. Diagnostic value for coronary artery disease of chest pain during dipyridamole-thallium stress testing. Am J Cardiol 1988; 61:43-45.
- 45 Iskandrian AS, Heo J, Nguyen T, et al. Assessment of coronary artery disease using single-photon emission computed tomography with thallium-201 during adenosine-induced coronary hyperemia. Am J Cardiol 1991; 67:1190-1194.
- 46 Pennell DJ, Underwood SR, Swanton RH, et al. Dobutamine thallium myocardial perfusion tomography. J Am Coll Cardiol 1991; 18:1471- 1479.
- 47 Young M, Pan W, Wiesner J, et al. Characterization of arbutamine: a novel catecholamine stress agent for diagnosis of coronary artery disease. Drug Dev Res 1994; 32:19-28.
- 48 Marwick TH. Arbutamine stress testing with closed loop drug delivery: toward the ideal or just another pharmacologic stress technique? J Am Coll Cardiol 1995; 26:1176-1179.
- 49 Webster MW, Makaroun MS, Steed DL, et al. Compromised cerebral blood flow reactivity is a predictor of stroke in patients with symptomatic carotid artery occlusive disease. J Vasc Surg 1995; 21:338-345.
- 50 Yonas H, Smith HA, Durham SR, et al. Increased stroke risk predicted by compromised cerebral blood flow reactivity. J Neurosurg 1993; 79:483-489.
- 51 Detre JA, Samuels OB, Alsop DC, et al. Noninvasive magnetic resonance imaging evaluation of cerebral blood flow with acetazolamide challenge in patients with cerebrovascular stenosis. J Magn Reson Imaging 1999; 110:870-875.
- 52 Cikrit DF, Dalsing MC, Lalka SG, et al. The value of acetazolamide single photon emission computed tomography scans in the preoperative evaluation of asymptomatic critical carotid stenosis. J Vasc Surg 1999; 30:599-605.
- 53 Ohnishi T, Yano T, Nakano S, et al. Acetazolamide challenge and technetium-99m-ECD versus iodine 123-IMP SPECT in chronic occlusive cerebrovascular disease. J Nucl Med 1997; 38:1463-1467.
- 54 Burt RW, Witt RM, Cikrit D, Reddy RV. Carotid artery disease: evaluation with acetazolamide-enhanced Tc-99m HMPAO SPECT. Radiology 1992; 182:461-466.